April 7, 2011 -- Allergy Therapeutics PLC (AGY), the specialist pharmaceutical company focused on allergy vaccination, is pleased to announce that it has submitted a Marketing Authorisation Application (‘MAA’) for Grass MATA MPL (a new formulation of Pollinex® Quattro) in Switzerland.
The MAA has been submitted to the Swiss regulatory authority, Swissmedic, and, on approval, the product will be distributed by Swiss-based Teomed AG, acquired by the Company in 2010. The Swiss allergy vaccine market is estimated to be worth between £8-10 million.
The Company’s flagship product, Pollinex Quattro, is sold across Europe on a named patient basis and consists of just 4 injections over 3 weeks, offering sufferers a safe and effective therapy with a much more convenient treatment regime than is currently available.
Manuel Llobet, Chief Executive of Allergy Therapeutics, said:
“This is our 12th MAA submission in 2 years and marks another strategic milestone for the Company as not only does it represent the first submission of the Grass MATA MPL MAA outside the EU, it also leverages the distribution capabilities of Teomed AG, our Swiss-based distributor, acquired by the Company in 2010.”
For further information
Allergy Therapeutics +44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Nomura Code Securities +44 (0) 207 776 1200
Juliet Thompson/ Clare Terlouw
Financial Dynamics +44 (0) 207 831 3113
Ben Brewerton/ Susan Quigley
About Allergy Therapeutics
Allergy Therapeutics plc is a London Stock Exchange (AIM) listed, integrated specialist pharmaceutical company focused on allergy vaccination. It has a growing, profitable business achieving sales of allergy vaccines of £41 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.
About MATA MPL and Pollinex® Quattro
MATA MPL is a new formulation of Pollinex® Quattro with a smaller injection volume; it is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment. It is a family of specific standardised vaccines representing a potentially extensive franchise for Allergy Therapeutics and is a novel entrant in the multibillion dollar global allergy market. Pollinex Quattro is currently available in Europe on a named patient basis.
About Allergy Vaccination
Allergy vaccination or immunotherapy is an effective way of modifying or avoiding disease by influencing the immune system. It is essentially a reinforcement of the body's own defence mechanisms and is similar to preventative vaccination against infectious disease; an area of medicine that has met with spectacular success. In allergy vaccination the mechanism is regarded as a correction of the immune system towards a more normal, non-allergic, response.
Allergy vaccination treats the underlying cause of the problem and provides a patient benefit which can be long lasting. The World Health Organisation recognises allergy vaccination as the only treatment to target the immunological cause of allergy with the ability to modify disease progression (to more severe allergy and to asthma), decreasing symptoms in the short term and offering long term anti-inflammatory benefits which prevent the development of persistent disease. Allergy vaccination, therefore, has the potential of offering patients a cure for their disease.
Holborn Gate, 26 Southampton Buildings
London, WC2A 1PB
D +44 (0)20 7269 7125